 III. To detect the levels of oxaliplatin-deoxyribonucleic acid DNA adducts induced by oxaliplatin microdosing in peripheral blood mononuclear cells PBMCs, and correlate the results with patient response and progression free survival on oxaliplatin-based chemotherapy. 